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What’s new? 
 People with type 2 diabetes are at an elevated risk of being affected by cardiovascular 
disease.  
 Cardiovascular disease is the leading cause of co-morbidity and death among people with 
type 2 diabetes. 
 Cost comparisons are usually between two groups of people with type 2 diabetes, those 
with and without cardiovascular disease.  
 The majority of studies take a cardiovascular disease prevalence-based approach to 
estimating the cost of illness. 
 
Abstract 
Aim To compare costs for three groups of people with type 2 diabetes, those at high risk of future 
cardiovascular disease, those without cardiovascular disease and those with established 
cardiovascular disease, and to also compare costs incurred by people with type 2 diabetes with an 
incident cardiovascular disease event with those who remain incident event-free over a 3-year 
period. 
Methods Data about people with type 2 diabetes in Scotland were obtained from the Scottish Care 
Information Diabetes registry. Data linkage was used to retrieve information on healthcare 
utilization, care home use and deaths. Productivity effects were estimated for those of non-
pensionable age. We estimated costs over 12 months (prevalent cardiovascular disease) and 3 years 
from incident cardiovascular disease event. 
Results Mean annual cost per person with established cardiovascular disease was £6900, £3300 for a 
person at high risk of future cardiovascular disease, and £2500 for a person without cardiovascular 
disease and not at high risk. In year 1, the cost of an incident cardiovascular disease event was £16 
700 compared with £2100 for people without an incident event. Over 2 years, the cumulative costs 
were £21 500 and £4200, and by year 3, £25 000 and £5900, respectively. 
Conclusions Cardiovascular disease in people with type 2 diabetes places a significant financial 
burden on healthcare and the wider economy. Our results emphasize the financial consequences of 
cardiovascular disease prevention strategies.  
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<H1>Introduction 
Cardiovascular disease (CVD) is the leading cause of co-morbidity and death among people with type 
2 diabetes [1]. People with type 2 diabetes are at increased risk and are disproportionally affected by 
CVD [2-5]. In addition to a reduction in quality of life and life expectancy, morbidity associated with 
CVD places significant burden on health services and the wider economy, as highlighted in a recent 
systematic review on the economic burden of CVD among people with type 2 diabetes [6]. This 
review concluded that only a few of the studies included productivity costs [6]. The majority of 
studies were undertaken over a decade ago, however, the treatment landscape in type 2 diabetes 
changes rapidly. In addition, comparisons made in the literature were between people with and 
without CVD. Prevention is also important, and hence inclusion of a third group, that is, people at 
high risk of developing CVD, will add significantly to the existing evidence on costs associated with 
prevalent CVD in people with type 2 diabetes. In addition, it is not known how costs and the 
composition of these costs develop over time after an incident CVD event.   
 
Therefore, this study aims to provide a comprehensive analysis of the cost of both prevalent and 
incident CVD in people with type 2 diabetes. For prevalent CVD, we compare the cost of illness for a 
12-month period for three groups of people with type 2 diabetes: those with no CVD, those at high 
risk of developing CVD, and those with established CVD. The second analysis compares costs 
incurred by people with type 2 diabetes who experience an incident CVD event with those who 
remain CVD event-free over a 3-year period. We also provide evidence on the composition of overall 
costs over that time period.   
 
<H1>Methods 
<H2>Data sources  
We utilized the population-wide Scottish Care Information–Diabetes (SCI–Diabetes) database to 
obtain information about people with type 2 diabetes [7]. SCI–Diabetes is a real-time clinical 
information system tracking clinical information with more than 99% case ascertainment. It also 
contains socio-demographic and prescribing data. The Community Health Index, a universal national 
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<H2>Cohort definitions 
<H3>Prevalent CVD 
Using a cross-sectional study design, we included all people with type 2 diabetes who were alive on 
1 July 2015. Based on a 10-year lookback period, people were classified into three groups: 1) having 
established CVD, 2) being at high risk of future CVD, and 3) being CVD-free and not at high risk of 
future CVD. Observations were censored at death or upon incident CVD event. Prevalent CVD was 
established using inpatient admission and primary care records (see the supporting information for 
International Classification of Diseases [ICD]-10 codes). Risk of future CVD was defined using SCI–
Diabetes and primary care records (read codes) if people with type 2 diabetes aged >60 years also 
met one of the following criteria: duration of type 2 diabetes for >5 years, HbA1c > 9%, hypertension 
(defined as blood pressure > 130/80 mm Hg [if no formal diagnosis of hypertensive disease]), 
dyslipidaemia (defined as total cholesterol > 9.0 mmol/l, non-HDL > 7.5 mmol/l, triglycerides 4.5–9.9 
mmol/l, pure hypercholesterolemia [E78.0], pure hyperglyceridaemia [E78.1], mixed hyperlipidaemia 
[E78.2], other hyperlipidaemia [E78.4], unspecified hyperlipidaemia [E78.5], other lipoprotein 
metabolism disorders [E78.89], unspecified disorder of lipoprotein metabolism [E78.9]), 
albuminuria, smoking status (smoker vs. non-smoker), BMI > 30 kg/m2, >2 drugs specific to CVD, 
estimated GFR < 60 ml/min/1.73m2, diabetic retinopathy, left ventricular dysfunction, left 
ventricular hypertrophy or angina. For these variables, values that were nearest to 1 January were 
used with a lookback period of 2 years and the most recent value was used for each individual [8].  
 
<H3>Incident CVD 
People alive with type 2 diabetes at any point from 1 January 2010 to 30 June 2015 were included 
and followed up for a maximum of 3 years, during which occurrence of the first CVD event was 
recorded. A 10-year lookback period was used to exclude people with a previous history of CVD. CVD 
events were defined using standard definitions as defined for the prevalent cohort above [8]. 
Observations were censored at death or end of study (June 2016). For people not experiencing a 
CVD event during follow-up, the study midpoint (2013) was used as their inception date, allowing for 
the maximum follow-up of 3 years.  
 
<H2>Health and social care utilization 
Inpatient admissions and day cases including information on diagnostic codes (ICD-10), length of 
acute hospital stay, speciality, health board area and discharge destination were obtained from 
Scottish Morbidity Records [9]. Per diem costs for 2015/2016 were obtained from the Scottish 
Health Service Costs [10] and mapped to health board and specialty. Prescribing data were retrieved 
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[11] and were assigned to prescribed items using British National Formulary codes. To derive an 
estimation of annual frequency of primary care visits, we used a validated algorithm based on the 
Charlson Co-morbidity Index [12]. Primary care costs were assigned to each visit using published 
costs from the Personal Social Services Research Unit [13]. Dependency status was derived from the 
discharge destination in Scottish Morbidity Records. The Scottish Care Home census confirms that, 
once admitted to a care home, only 5% of patients return to independent living [14]. Therefore, we 
applied 95% of the mean weekly care costs to all patients in care homes for the duration of the study 
or until death [15]. For people of working age we applied a weekly cost of £560 (average adult wage 
[16]) for the period that patients were either in hospital or a care home and thus unable to work. 
Mortality data were obtained from National Records for Scotland. 
 
<H2>Statistical Analyses 
Generalized Linear Models with a gamma distribution and an identity link function were employed 
to estimate the contribution of different cost categories to total costs for each of the three groups. 
No imputation was carried out in cases of missing data items except for co-morbidity. We adjusted 
for clinical (duration of diabetes, blood pressure, HbA1c, total cholesterol and Charlson Co-morbidity 
Index) and demographic (age, sex, Scottish Index of Multiple Deprivation [17]) factors. Mean annual 
costs for prevalent CVD over a 12-month period and confidence intervals were obtained from 
predicted values of these regression models. Similarly, we obtained mean costs for year 1, 2 and 3 
since incident CVD event. All cost estimates were reported in 2015/2016 prices. All analyses were 




Of 244 752 people alive with type 2 diabetes as of 1 July 2015 (median duration of diabetes 7.7 
years), we identified 73 037 people with type 2 diabetes with established CVD, 141 428 at high risk 
of CVD, and 30 287 with no CVD and not at high risk (Table S1). The mean annual cost for a person 
without CVD and not at high risk was £2500 (95% CI: £700–£8000), £3300 (95% CI: £1000–£16 100) 
for a person at high risk of future CVD, and £6900 (95% CI: £1600–£29 700) for a person with 
established CVD (Table 1). This pattern of increasing costs in connection with CVD was observed 
across all age groups. Across (non-exclusive) CVD categories and excluding the small number of 
people with hypertensive diseases, people with peripheral arterial disease and heart failure as their 
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revascularization procedures incurred the lowest costs (Table 2). However, the wide confidence 
intervals reflect the variation in costs. 
[Insert TABLE 1] 
[Insert TABLE 2] 
 
For people with established CVD, hospital admissions accounted for the majority of annual costs 
(Figure 1). Costs related to hospital admission accounted for a smaller share of overall costs for 
people with no CVD, with prescription and primary care costs accounting for a larger proportion of 
total costs compared with people with established CVD (Figure 1). The distribution of individual cost 
elements for people at high risk of CVD is similar to that of people with no CVD, except that their 
hospital costs represented a greater share of overall costs and their primary care costs a smaller 
share. Indirect costs due to lost productivity were found to be a very small component of overall 
costs for all groups (0.2% across all three groups). A breakdown of costs by CVD type and healthcare 
sector is provided in Table 3. 
 
[Insert Figure 1] 
 
[Insert TABLE 3] 
 
<H2>Incident CVD 
Our analysis included 245 428 people with type 2 diabetes with no previous history of CVD, 35 322 
of whom experienced an incident CVD event during follow-up. Baseline characteristics are shown in 
Table S2. We present mean annual costs by subgroups of age and type of CVD incident event in 
Table 3 alongside 3-year mortality and incidence rates. People experiencing an incident event were 9 
years older on average compared with individuals not experiencing a CVD event (Table S2). These 
people have also had their type 2 diabetes diagnosis for longer.  
 
Mean costs per person after 3 years since the incident CVD event (£25 000) compared with costs for 
individuals who do not experience an incident CVD event (£5900) were substantially higher (Table 3). 
Although costs in year 1 include those incurred during the incident event, we find that this pattern 
persists, and also that costs generally increase with increasing age. Cerebrovascular incident events 
were associated with the highest cost over 3 years (£37 900) and revascularization procedures were 
associated with the lowest cost (£17 500). Large cost increments from year 1 to year 3 were found 
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year 1 since incident event. A different pattern is observed for incident events that may require a 
higher upfront cost, such as revascularization procedures, where costs after 3 years show a smaller 
increase (Table 4). The overall CVD event rate was 30.81 per 1000 person-years and was found to be 
highest for ischaemic heart disease (15.35 per 1000 person-years). The CVD categories in Table 4 are 
not exclusive: people may be counted in more than one category depending upon the diagnosis 
made at incident event. 
 
<Insert TABLE 4> 
 
In the 12-month period following the incident CVD event, hospital and residential care costs 
accounted for the largest share of total costs. In years 2 and 3, residential and primary care 
accounted for a larger proportion than in year 1, with hospital care still being the main contributor 
(Figure 2). Prescription costs remained relatively proportionately constant over time for individuals 
experiencing an incident CVD event, but proportionately reduced in relation to other cost categories 
for those without an event, while hospital costs increased. For both groups, costs associated with 
lost productivity only accounted for 1–2% of total costs (Figure 2). All analyses were age-adjusted. 
[Insert Figure 2] 
 
 
Sector-specific costs by type of incident CVD event and year are presented in Table 5. Figure S1 
provides an overview of the sector-specific cost contributions to overall costs at 3 years for people 
who experienced an incident event. People without a CVD event incurred costs distributed evenly 
between primary, hospital, residential care and prescriptions. With the exception of hypertensive 
diseases, the distribution of cost categories is very similar among CVD types (Figure S1).  
<Insert TABLE 5> 
<H1>Discussion 
 
Prevalent and incident CVD in people with type 2 diabetes place a significant financial burden on 
health and social care services and the wider economy. Using national population level data, we 
identified both prevalent and incident CVD events in people with type 2 diabetes and estimated 
costs to the healthcare system and the wider economy. The magnitude of that burden varies among 
groups. Our findings suggest that a person with type 2 diabetes at high CVD risk costs the economy 
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risk. If CVD is present, the additional annual cost rises to £4400, excluding the costs associated with 
earlier CVD event(s).  
 
To date, only a limited number of UK studies have analysed the economic burden of CVD in people 
with type 2 diabetes [19,20]. Hex et al. [19] reported costs for hospital admission and procedures at 
a population level and Alva et al. [20] at an individual level. In comparison with our study, the 
sample sizes were smaller and the CVD categories differed. However, in terms of secondary care 
costs in the first year, it is possible to make comparisons. For ischaemic heart disease, Alva et al. 
report a cost of £9800 in 2012 prices (£10 100 when inflated using the hospital and community 
service index), which is close to our estimate of £11 000.   
 
Rather than just comparing between groups of people with and without CVD, we were able to 
identify a third group of people with type 2 diabetes at high risk of future CVD, thus providing a 
more comprehensive picture. 
 
The type of incident CVD event also impacts on costs and the highest costs are incurred during the 
incident event. However, substantial cost differentials between people with type 2 diabetes with 
and without CVD event continue to show beyond incident event over a 3-year follow-up. This seems 
to be caused by the initial high costs associated with the incident event and by complications that 
develop once CVD is established. The composition of overall costs changes over a 3-year follow-up 
for people with type 2 diabetes with an incident CVD event with hospital costs decreasing, and costs 
for residential care increasing over time. For people who remained CVD event-free over a 3-year 
period, hospital costs increased, whereas prescription costs decreased. Costs due to lost productivity 
are small, as a majority of patients is above pensionable age. We expanded on earlier research, 
which reported overall annual costs of $3400 and $9700 for treating people with type 2 diabetes and 
CVD compared with those without CVD [6]. Our estimated cost differences were higher than those 
reported in the systematic review; however, most studies only considered direct costs, and the time 
periods during which cost differences were measured varied greatly [6].     
<H2>Strengths and limitations 
We were able to include all main cost components for direct and indirect medical costs, estimated 
costs due to lost productivity, and costs for care home stays. However, we appreciate that there may 
be uncertainty, in particular regarding the frequency of primary care contacts, as these were 
estimated using an existing algorithm from the literature, and also concerning costs due to lost 
productivity, as the estimation relied on the assumption that only a hospitalization would lead to 
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the financial burden of CVD in type 2 diabetes, emphasizing the importance of effective prevention 
strategies and providing guidance to inform risk stratification to guide treatment decisions. 
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Definition of established cardiovascular disease.  
Table S1 Demographic characteristics and risk factors by cardiovascular disease status in people with 
type 2 diabetes. 
Table S2 Patient characteristics at study entry (mean (SD); %). 
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Costs (£) over 12 months per 
patient 
Mean (95% CI) 
        
All (n = 244 
752) 
 <60 years 
(n = 72 
055) 
 60–69 
years (n = 
70 631) 
 70–79 years (n = 64 
839) 




(n = 73 037) 
 6900 (1600–29 700) Established 
















= 18 217) 
 10 100 (2100–40 400) 
High risk (n 
= 141 428) 
 3300 (1000–16 100) High risk (n 
= 49 094) 
 1800 (900–
4900) 
High risk (n 




High risk (n = 33 403)  4400 
(1400–  
22 900) 
High risk (n = 
16 749) 
 7100 (1800–38 800) 
None (n = 
30 287) 









None (n = 6091)  3500 
(1100–
19 400) 
None (n = 
2261) 
 5900 (1300–36 600) 
 
Table 2 Total mean cost for people with type 2 diabetes in Scotland for 2015–2016 by cardiovascular disease (CVD) type (rounded to the nearest £100) 
First CVD event N Costs (£) over 12 months per patient 
Mean (95% CI) 
Ischaemic heart disease  44 948 5800 (1500–26 300) 
Heart failure 2736 8600 (1500–38 300) 
Cardiac arrhythmia  9855 8100 (2000–34 000) 
Cerebrovascular disease or transient ischaemic attack  8451 5800 (1400–21 700) 
           Cerebrovascular disease  6123 7900 (1900–32 000) 
           Transient ischaemic attack  2328 6200 (1600–35 700) 
Peripheral arterial disease  3938 9200 (1800–40 900) 
Revascularization procedures  3104 4700 (1300–20 600) 
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Table 3 Annual costs by cost component and first cardiovascular disease (CVD) type for people with 
type 2 diabetes in Scotland for 2015–2016 (rounded to the nearest £100) 
 Costs (£) over 12 months – mean (95% CI) 
CVD type Secondary care  Primary care  Residential 
care* 
Prescriptions  Productivity*  




700 (175–1300) 400 (0–1400) 1000 (0–
3200) 
 0 (0–0) 
Cerebrovascular disease (n = 
6123) 
 
5300 (0–51 900) 700 (200–1300) 500 (0–4300) 900 (0–3300) 0 (0–0) 
Cerebrovascular disease or 
transient ischaemic attack (n = 
8451) 
5100 (0–49 000) 700 (200–1300) 400 (0–2100) 900 (0–3300) 0 (0–0) 
Heart failure (n = 2736) 
 
5600 (0–50 700) 700 (200–1400) 300 (0–0) 970 (0–3300) 0 (0–0) 
Hypertensive diseases (n = 5) 5700 (100–10 
300) 




Ischaemic heart disease (n = 44 
948) 
 
3900 (0–38 400) 700 (200–1300) 200 (0–0) 1000 (0–
3400) 
0 (0–0) 
Peripheral arterial disease (n = 
3938) 
6500 (0–58 700) 700 (200–1300) 280 (0–0) 1000 (1000–
3500) 
0 (0–0) 




600 (200–1300) 200 (0–0) 900 (0–3100) 0 (0–0) 
Transient ischaemic attack (n = 
2328) 
4600 (0–45 000) 700 (300–1300) 200 (0–0) 900 (0–3500) 0 (0–0) 
These values do not sum to the total costs given in the main text. They are regression-based 
estimates. 
*These values reflect the age of incident event occurring typically after state pension eligibility age 
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Table 4 Mean annual costs (cumulative); 3-year mortality; incidence rates in people with type 2 
diabetes without previous history of cardiovascular disease (CVD) in Scotland 2010–2015 – based on 
study entry date (rounded to the nearest £100) 
 No incident CVD event 
Mean cost (£) and 95% CI 
Incident and subsequent CVD 
Mean cost (£) and 95% CI 
All n = 245 428   
3-year mortality   25.25% 
Event rate per 1000 person-years* 30.81 
  Year 1  2100 (1000–6100) 16 700 (6700–41 700) 
  Year 1 and 2 4200 (2000–11 900) 21 500 (9000–50 900) 
  Year 1, 2 and 3 5900 (2800–16 500) 25 000 (10 700–57 100) 
<60 years (n = 104 078) 
  
  Year 1  1400 (900–2800) 11 200 (6100–26 100) 
  Year 1 and 2 3000 (2000–5600) 14 400 (8100–31 300) 
  Year 1, 2 and 3 4000 (2700–7500) 16 800 (9700–35 200) 
60–69 years (n = 68 626) 
  
  Year 1  1900 (1200–4900) 13 800 (7100–31 000) 
  Year 1 and 2 4000 (2400–9700) 17 400 (9400–37 300) 
  Year 1, 2 and 3 5600 (3500–13 400) 20 100 (11 100–41 700) 
70–79 years (n = 51 769) 
  
  Year 1  2900 (1600–8800) 17 400 (8500–39 400) 
  Year 1 and 2 5900 (3200–16 600) 22 900 (12 000–48 900) 
  Year 1, 2 and 3 8300 (4600–23 000) 27000 (14 500–55 300) 
≥80  (n = 20 955)   
  Year 1  4100 (2000–12 400) 25 200 (12 200–57 800) 
  Year 1 and 2 8200 (4200–23 400) 32 300 (16 700–68 700) 
  Year 1, 2 and 3 11 500 (6000–32 200) 37 300 (20 000–76 900) 
   
Cerebrovascular disease  (n = 4172)                               
3-year mortality  30.37% 
Event rate per 1000 person-years* 3.64 
  Year 1   29 600 (14 700–62 300) 
  Year 1 and 2  34 600 (17 600–71 600) 
  Year 1, 2 and 3  37 900 (19 400–78 700) 
Ischaemic heart disease (n = 17 594)                   
3-year mortality  21.26% 
Event rate per 1000 person-years* 15.35 
  Year 1   12 500 (6500–27 500) 
  Year 1 and 2  16 700 (8600–35 900) 
  Year 1, 2 and 3  19 800 (10 200–42 100) 
Transient ischaemic attack (n = 1370)                          
3-year mortality  17.88% 
Event rate per 1000 person-years* 1.2 
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  Year 1 and 2  14 800 (7700–30 000) 
  Year 1, 2 and 3  18 500 (9700–36 700) 
Peripheral arterial disease (n = 3114)                              
3-year mortality 27.65% 
Event rate per 1000 person-years* 2.72 
  Year 1   21 600 (10 300–47 900) 
  Year 1 and 2  28 200 (13 500–61 100) 
  Year 1, 2 and 3  32 700 (15 700–69 100) 
Heart failure (n = 4205)                                             
3-year mortality  38.10% 
Event rate per 1000 person-years* 3.67 
  Year 1   20 100 (9200–43 300) 
  Year 1 and 2  25 900 (11 700–54 700) 
  Year 1, 2 and 3  29 900 (13 600–62 000) 
Cardiac arrhythmia (n = 10 260)                                       
3-year mortality  30.02% 
Event rate per 1000 person-years* 8.95 
  Year 1   17 600 (8400–38 600) 
  Year 1 and 2  22 900 (11 100–48 300) 
  Year 1, 2 and 3  26 700 (13 100–55 200) 
Hypertensive diseases (n < 10)                                        
3-year mortality  66.67% 
Event rate per 1000 person-years* 0.00 
  Year 1   40 000 (28 700–50 600) 
  Year 1 and 2  40 000 (28 700–50 600) 
  Year 1, 2 and 3  40 000 (28 700–50 600) 
Revascularization procedures (n = 3636)                        
3-year mortality  9.85% 
Event rate per 1000 person-years* 3.17 
  Year 1  12 100 (6400–27 900) 
  Year 1 and 2  15 000 (8100–33 600) 
  Year 1, 2 and 3  17 500 (9600–38 300) 
Cerebrovascular disease/transient ischaemic attack (n = 5435)  
3-year mortality  27.28% 
Event rate per 1000 person-years* 1.2 
  Year 1   15 700 (8900–31 800) 
  Year 1 and 2  21 000 (2000–42 400) 
  Year 1, 2 and 3  24 900 (13 500–48 700) 
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Table 5 Mean cost (cumulative) by cost component and cardiovascular disease (CVD) type (rounded 
to the nearest £100) 
Cost type/CVD type  Costs (£) over 12 months  
Mean (95% CI)*  
Costs (£) over 24 months  
Mean (95% CI)* 
Costs (£) over 36 months  
Mean (95% CI)* 
Secondary care    
  Cerebrovascular disease  25 000 (700–114 
900) 28 300 (700–129 500) 
30 600 (800–139 
100) 
  Ischaemic heart disease  11 000 (100–63 400) 13 900 (100–80 600) 16 100 (200–91 200) 
  Transient ischaemic attack  8600 (100–65 200) 12 000 (100–78 900) 14 700 (200–90 200) 
  Peripheral arterial disease 
18 500 (100–98 300) 23 400 (100–116 800) 
26 500 (200–131 
300) 
  Heart failure  
17 000 (100–79 900) 21 100 (200–101 900) 
24 000 (400–112 
600) 
  Cardiac arrhythmia  
15 600 (100–84 200) 19 300 (100–100 700) 
22 100 (200–122 
500) 
  Hypertensive diseases  16 200 (3800–32 
000) 
27 100 (14 600–34 
300) 
27 200 (14 700–34 
400) 
  Revascularization procedures  11 200 (100–74 800) 13 100 (100–86 300) 14 700 (200–99 200) 
  Cerebrovascular disease or transient 
ischaemic attack   
21 100 (100–105 
800) 24 500 (200–121 100) 
26 900 (400–130 
000) 
Primary care 
   
  Cerebrovascular sisease 600 (0–1200) 1100 (0–2300) 1500 (0–3500) 
  Ischaemic heart disease  500 (0–1200) 1000 (0–2200) 1500 (0–3300) 
  Transient ischaemic attack 600 (200–1200) 1200 (200–2500) 1800 (200–3600) 
  Peripheral arterial disease 600 (0–1200) 1100 (0–2400) 1600 (0–3500) 
  Heart failure  600 (0–1200) 1100 (0–2500) 1600 (0–3700) 
  Cardiac arrhythmia  600 (0–1200) 1100 (0–2300) 1500 (0–3300) 
  Hypertensive diseases  500 (100–700) 800 (200–1400) 1100 (200–2100) 
  Revascularization procedures  500 (100–1000) 1000 (100–2100) 1400 (100–3100) 
  Cerebrovascular disease or transient 
ischaemic attack   600 (0–1200) 1100 (0–2300) 1600 (0–3500) 
Residential care 
   
  Cerebrovascular disease  700 (0–13 500) 1300 (0–20 000) 1700 (0–25 000) 
  Ischaemic heart disease  300 (0–0 ) 500 (0–0) 700 (0–0) 
  Transient ischaemic attack  300 (0–0) 500 (0–0) 700 (0–0) 
  Peripheral arterial disease  300 (0–0) 500 (0–1400) 800 (0–3900) 
  Heart failure  400 (0–1300) 600 (0–4000) 800 (0–5300) 
  Cardiac arrhythmia  500 (0–3200) 900 (0–7100) 1200 (0–10 800) 
  Hypertensive diseases  0 (0–0) 4100 (0–11 600) 4100 (0–11 600) 
  Revascularization procedures  100 (0–0) 300 (0–0) 400 (0–0) 
  Cerebrovascular disease or transient 
ischaemic attack   600 (0–10 200) 1100 (0–15 600) 1500 (0–19 300) 
Prescriptions 
   
  Cerebrovascular disease  800 (0–2900) 1300 (0–5200) 1600 (0–6800) 
  Ischaemic heart disease  900 (0–3100) 1600 (0–5900) 1900 (0–7700) 
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  Peripheral arterial disease  900 (0–3100) 1600 (0–5900) 2000 (0–7900) 
  Heart failure 900 (0–3500) 1600 (0–6500) 2000 (0–8400) 
  Cardiac arrhythmia  800 (0–3000) 1400 (0–5400) 1700 (0–7000) 
  Hypertensive diseases 2000 (900–3000) 3000 (3000–3100) 4100 (3200–5000) 
  Revascularization procedures 800 (0–3000) 1300 (0–5200) 1700 (0–6800) 
  Cerebrovascular disease or transient 
ischaemic attack   800 (0–3000) 1400 (0–5500) 1700 (0–7100) 
Productivity 
   
  Cerebrovascular disease 600 (0–6200) 700 (0–7000) 700 (0–7700) 
  Ischaemic heart disease 300 (0–2200) 300 (0–2700) 400 (0–3100) 
  Transient ischaemic attack  100 (0–1000) 200 (0–1700) 200 (0–2400) 
  Peripheral arterial disease  600 (0–6100) 800 (0–7700) 900 (0–8800) 
  Heart failure  300 (0–3500) 400 (0–4300) 500 (0–5000) 
  Cardiac arrhythmia  200 (0–2300) 300 (0–2900) 300 (0–3300) 
  Hypertensive diseases  100 (0–400) 4800 (0–13 800) 4800 (0–13 800) 
  Revascularization procedures  600 (0–5400) 700 (0–6200) 800 (0–7100) 
  Cerebrovascular disease or transient 
ischaemic attack    500 (0–5600) 600 (0–6100) 600 (0–6900) 
*Non-parametric CIs have been estimated.  
 
Figure 1 Contribution of cost categories to average total annual costs for patients with no 
cardiovascular disease (CVD), at high risk of CVD or with established CVD. 
Figure 2 Contribution to average total costs of different cost categories over years 1, 2 and 3 for 
people experiencing an index cardiovascular disease (CVD) event (left panel) and those not 





Definition of established CVD  
Established CVD was defined as having codes for any cause of admission for chronic ischaemic heart 
disease (ICD-10 I20-I25), cerebrovascular disease including transient ischaemic attack (ICD-10 I60-63, 
I66, I69 & G45), peripheral arterial disease (ICD-I70.2 and I73.9), heart failure (I11.0, I13 I50), cardiac 
arrhythmia (I48, I49), hypertensive heart disease (I13.0, I15.0) or procedure codes for 
revascularisation procedures of coronary, carotid or lower limb arteries. In addition, primary care 
records were also queried for corresponding Read codes for coronary heart disease, cerebrovascular 
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